Graham Boulnois

About

Professor Graham Boulnois joined SVLS as a Venture Partner in 2001 and became a Partner in 2004. Graham is Chairman of KalVista Pharmaceuticals Ltd, and a Director of Affinium Pharmaceuticals, Karus Pharmaceuticals Ltd and Vantia Pharmaceuticals Ltd. Previously, he was a Director at Lorantis Ltd, Alantos Inc (prior to its sale to Amgen) and ESBATech AG (prior to its sale to Alcon Inc), Delenex Therapeutics AG, and was Chairman and a Director of Oxagen Ltd. He had responsibility for overseeing the investment in Cellzome, prior to its sale to GSK.

Investment Focus

Location

London, UK